Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
Vaccines and Related Biological Products Advisory Committee reviewed data from the biologics license application for RBX2660 RBX2660 is an investigational…
-
-
Partnering to Help Drive Reproductive Medicine and Maternal Health Forward
Ferring to share insights and expertise across a range of timely and critical topics at the Women’s Health Innovation Summit…
-
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based Live Biotherapeutic
Vaccines and Related Biological Products Advisory Committee will hold meeting on September 22, 2022 RBX2660 is an investigational microbiota-based live…
-
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
New subgroup analyses presented at Digestive Disease Week® (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase…
-
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022
Parsippany, NJ – May 11, 2022 – Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an…
-
Data for Ferring’s RBX2660 Published in BMC Infectious Diseases: “Durable Reduction of Clostridioides difficile Infection Recurrence and Microbiome Restoration after Treatment with RBX2660: Results from an Open-Label Phase 2 Clinical Trial”
Primary objective was to compare treatment success of RBX2660 to historical control group A key secondary outcome was the safety…
-
Ferring Announces Investment in Robyn, an Online Community that Provides Access to Fertility and Parental Wellness Resources
Ferring Pharmaceuticals has finalized a two-year investment agreement including an acquisition option with Robyn. Together, Ferring and Robyn will provide…
-
Frontiers in Microbiology Publishes Article Detailing Novel Microbiome-based Biomarker of Post-Antibiotic Disruptions in Gut Microbiota
Ferring’s Microbiome Health Index™ is a promising tool that measures disrupted gut microbiota after antibiotic treatment, subsequent gut microbiota restoration,…
-
Ferring Pharmaceuticals Supports the Proclamation of November as Clostridioides difficile Infection Awareness Month in New Jersey and Minnesota
In conjunction with C. Diff Infection Awareness Month, Ferring Pharmaceuticals launches new educational website Parsippany, New Jersey – November 11,…
-
Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021
New retrospective analysis found RBX2660 demonstrated efficacy and safety outcomes among a real-world population of C. difficile (CDI) patients, including…